FDA Drug Advertising Study Tracker

Regulatory NewsRegulatory NewsTrackersTrackers | 12 January 2015 |  By 

The US Food and Drug Administration (FDA) frequently studies consumer behavior, particularly as it relates to how members of the public (and medical professionals) understand pharmaceutical advertising. Our FDA Drug Advertising Study Tracker keeps tabs on these studies and explains what they're trying to accomplish in plain terms.


Date Topic Study Summary
January 2012 Corrective Advertising Study to assess whether and how corrective advertising—used to correct information in a previous ad—works.
October 2012 Promotional Ads and Healthcare Professionals Study to assess how advertisements and promotional materials affect prescribing habits.
May 2013 Composite Scores Study to assess whether and how consumers understand "composite scores" used in DTC advertising.
July 2013 Health Information Availability Assessment of how consumers find health information about prescription medication
October 2013 Adolescents and DTC Advertising Study to assess how adolescents interpret drug risk in DTC advertising
February 2014 Alternate Format for Major Risks in DTC Drug Ads Proposed study of whether FDA should allow DTC ads to contain only the major risks associated with a drug.
May 2014 Distractions in DTC Advertising Study to assess whether "distractions" in DTC advertisements can make a drug seem safer than it is.
November 2014 Effects of Repeated Exposure to DTC Advertising Study to assess how repeated exposure to a single drug ad changes consumer behavior over time.
November 2014 Impact of Spouse on Understanding of Drug Risks, Benefits Study to assess the "social contexts" a drug advertisement is seen in, with a focus on how a spouse can affect risk perception.
November 2014 Risk and Benefit Perception Scale Development Study to develop reliable measurements of how consumers assess the benefits and risks of drug products.
January 2014 Disclosure Regarding Additional Risks in DTC Prescription Drug TV Advertisements Study of how changes to DTC advertising—specifically limiting warnings to the major risks of a drug—might improve the advertisements.


© 2023 Regulatory Affairs Professionals Society.

Discover more of what matters to you

No taxonomy